HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael Thomas Selected Research

Febrile Neutropenia

1/2020Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
8/2014Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
3/2012Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
5/2007Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael Thomas Research Topics

Disease

132Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2024 - 06/2002
108Neoplasms (Cancer)
05/2024 - 04/2002
48Lung Neoplasms (Lung Cancer)
03/2024 - 04/2004
26Disease Progression
10/2023 - 03/2012
17Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2023 - 01/2011
16Neoplasm Metastasis (Metastasis)
01/2023 - 09/2003
12Adenocarcinoma of Lung
01/2023 - 11/2008
11Brain Neoplasms (Brain Tumor)
01/2024 - 08/2015
10Infections
10/2023 - 05/2007
9Neutropenia
06/2022 - 05/2007
9Fatigue
04/2021 - 03/2012
7Diarrhea
02/2018 - 11/2002
6Adenocarcinoma
12/2022 - 04/2012
6Fibrosis (Cirrhosis)
12/2022 - 01/2011
6Carcinoma (Carcinomatosis)
10/2022 - 04/2002
6Breast Neoplasms (Breast Cancer)
12/2021 - 12/2011
6Pneumonia (Pneumonitis)
10/2021 - 11/2002
6Exanthema (Rash)
02/2018 - 11/2002
5Anemia
06/2022 - 08/2013
5Carcinogenesis
01/2021 - 11/2002
5Malignant Mesothelioma
01/2021 - 01/2009
4Hematologic Neoplasms (Hematological Malignancy)
03/2024 - 05/2015
4Visceral Leishmaniasis (Kala Azar)
07/2023 - 01/2018
4Shoulder Pain
01/2023 - 12/2014
4Hemorrhage
01/2023 - 05/2004
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2021 - 07/2014
4Febrile Neutropenia
01/2020 - 05/2007
4Hypertension (High Blood Pressure)
01/2020 - 03/2011
4Pain (Aches)
11/2019 - 12/2016
4Asthma (Bronchial Asthma)
01/2016 - 01/2007
4Sarcoma (Soft Tissue Sarcoma)
03/2014 - 03/2012
3Inflammation (Inflammations)
01/2023 - 08/2008
3Dyspnea (Shortness of Breath)
01/2023 - 06/2013
3Chronic Obstructive Pulmonary Disease (COPD)
01/2023 - 06/2012
3Wounds and Injuries (Trauma)
04/2021 - 10/2017
3Body Weight (Weight, Body)
01/2021 - 02/2010
3Atherosclerosis
01/2021 - 01/2007
3Ovarian Neoplasms (Ovarian Cancer)
01/2020 - 07/2013
3Nausea
05/2017 - 11/2006

Drug/Important Bio-Agent (IBA)

28Biomarkers (Surrogate Marker)IBA
03/2024 - 06/2002
24Tyrosine Kinase InhibitorsIBA
03/2024 - 10/2010
19ErbB Receptors (EGF Receptor)IBA
03/2024 - 03/2005
18PlatinumIBA
02/2024 - 12/2005
16Proteins (Proteins, Gene)FDA Link
03/2024 - 07/2012
15Cisplatin (Platino)FDA LinkGeneric
10/2023 - 05/2007
13Immune Checkpoint InhibitorsIBA
01/2023 - 01/2019
13Pemetrexed (MTA)FDA Link
01/2023 - 05/2007
11Anaplastic Lymphoma KinaseIBA
05/2022 - 03/2014
9Adrenal Cortex Hormones (Corticosteroids)IBA
01/2023 - 01/2007
9Carboplatin (JM8)FDA LinkGeneric
01/2023 - 04/2002
9Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2019 - 03/2011
8DNA (Deoxyribonucleic Acid)IBA
05/2024 - 11/2008
8Bevacizumab (Avastin)FDA Link
01/2020 - 02/2014
7Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2018 - 03/2005
6CrizotinibIBA
10/2022 - 06/2013
6EnzymesIBA
11/2019 - 11/2002
5pembrolizumabIBA
04/2024 - 05/2019
5GlycodelinIBA
03/2024 - 08/2015
5Docetaxel (Taxotere)FDA Link
01/2024 - 08/2014
5Anti-Bacterial Agents (Antibiotics)IBA
10/2023 - 10/2021
5osimertinibIBA
10/2023 - 01/2021
5RNA (Ribonucleic Acid)IBA
08/2022 - 09/2007
5Phosphotransferases (Kinase)IBA
02/2022 - 03/2005
5AntigensIBA
05/2019 - 12/2011
5Gefitinib (Iressa)FDA Link
02/2018 - 12/2005
4iberdomideIBA
03/2024 - 10/2018
4Glycoproteins (Glycoprotein)IBA
03/2024 - 08/2015
4durvalumabIBA
02/2024 - 01/2020
4Peptides (Polypeptides)IBA
01/2024 - 07/2013
4130-nm albumin-bound paclitaxelIBA
01/2023 - 01/2020
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2023 - 09/2007
4CytokinesIBA
01/2023 - 05/2019
4Cell-Free Nucleic AcidsIBA
12/2022 - 01/2016
4Messenger RNA (mRNA)IBA
09/2022 - 08/2015
4GemcitabineFDA Link
04/2020 - 07/2015
4Etoposide (VP 16)FDA LinkGeneric
03/2020 - 04/2002
4RamucirumabIBA
01/2020 - 08/2014
3fedratinibIBA
11/2023 - 12/2021
3Tumor Biomarkers (Tumor Markers)IBA
10/2023 - 06/2002
3NivolumabIBA
12/2022 - 11/2019
3ceritinibIBA
10/2022 - 03/2014
3Transaminases (Aminotransferases)IBA
06/2022 - 06/2013
3BilirubinIBA
05/2022 - 01/2007
3AlbuminsIBA
01/2022 - 03/2014
3Transcription Factors (Transcription Factor)IBA
01/2021 - 03/2014
3Paclitaxel (Taxol)FDA LinkGeneric
03/2020 - 04/2010
3Thymidylate SynthaseIBA
09/2015 - 09/2012
3Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA
03/2013 - 12/2011
2Antineoplastic Agents (Antineoplastics)IBA
01/2024 - 01/2018

Therapy/Procedure

97Therapeutics
05/2024 - 11/2002
39Drug Therapy (Chemotherapy)
01/2024 - 04/2002
24Radiotherapy
01/2024 - 04/2002
13Immunotherapy
03/2024 - 05/2019
11Palliative Care (Palliative Therapy)
01/2023 - 01/2016
7Chemoradiotherapy
10/2023 - 12/2004
6Neoadjuvant Therapy
03/2024 - 04/2002
6Adjuvant Chemotherapy
06/2022 - 08/2004
3Liver Transplantation
03/2024 - 04/2007
3Cranial Irradiation
01/2017 - 08/2015
2Aftercare (After-Treatment)
03/2024 - 03/2011